PriceTargets.com logo

ObsEva - OBSV Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $8.40
  • Forecasted Upside: 4,841.18 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.17 As of 12/6/2022 01:00 AM ET
▼ -0.01 (-5.56%)

This chart shows the closing price for OBSV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ObsEva Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OBSV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OBSV

Analyst Price Target is $8.40
▲ +4,841.18% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for ObsEva in the last 3 months. The average price target is $8.40, with a high forecast of $12.00 and a low forecast of $1.00. The average price target represents a 4,841.18% upside from the last price of $0.17.

This chart shows the closing price for OBSV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 5 contributing investment analysts is to hold stock in ObsEva. This rating has held steady since September 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
6/15/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/13/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/12/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/12/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/10/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/8/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/7/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/7/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/30/2022HC WainwrightDowngradeBuy ➝ NeutralLow
8/1/2022Canaccord Genuity GroupDowngradeBuy ➝ Hold$12.00 ➝ $1.00Low
7/28/2022Cantor FitzgeraldDowngradeOverweight ➝ NeutralLow
6/21/2022HC WainwrightReiterated RatingBuy$11.00Low
6/3/2022Cantor FitzgeraldInitiated CoverageOverweight$6.00High
5/23/2022HC WainwrightReiterated RatingBuy$11.00High
4/26/2022Canaccord Genuity GroupInitiated CoverageBuy$12.00High
4/26/2022Canaccord Genuity GroupInitiated CoverageBuy$12.00High
3/28/2022AegisInitiated CoverageBuy$12.00High
3/28/2022HC WainwrightLower TargetBuy$15.00 ➝ $11.00Low
2/7/2022HC WainwrightReiterated RatingBuy$15.00Low
11/29/2021HC WainwrightLower TargetBuy$17.00 ➝ $15.00Low
9/17/2021WedbushReiterated RatingBuy$21.00High
9/15/2021HC WainwrightReiterated RatingBuy$17.00Medium
8/9/2021HC WainwrightReiterated RatingBuy$17.00Low
7/28/2021WedbushReiterated RatingBuy$21.00Low
7/2/2021WedbushReiterated RatingBuy$24.00N/A
1/12/2021WedbushReiterated RatingBuy$28.00Low
1/12/2021SVB LeerinkBoost TargetOutperform$4.00 ➝ $5.00Low
1/4/2021HC WainwrightLower TargetBuy$23.00 ➝ $17.00N/A
11/9/2020JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightMedium
10/5/2020HC WainwrightLower TargetBuy$36.00 ➝ $23.00High
8/14/2020WedbushReiterated RatingBuy$30.00High
7/7/2020SVB LeerinkLower TargetOutperform$7.00 ➝ $5.00High
7/7/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$18.00 ➝ $5.00High
7/6/2020BMO Capital MarketsDowngradeOutperform ➝ Market Perform$5.00 ➝ $4.00High
7/1/2020HC WainwrightReiterated RatingBuy$36.00Low
7/1/2020WedbushReiterated RatingBuy$30.00Low
6/5/2020HC WainwrightReiterated RatingBuy$36.00High
5/5/2020WedbushReiterated RatingBuy$30.00High
3/23/2020WedbushReiterated RatingBuy$40.00 ➝ $34.00Medium
3/23/2020HC WainwrightLower TargetBuy$40.00 ➝ $36.00Low
3/5/2020WedbushBoost TargetOutperform$36.00 ➝ $40.00High
1/21/2020WedbushReiterated RatingBuy$36.00High
1/21/2020HC WainwrightReiterated RatingBuy$40.00High
12/19/2019HC WainwrightReiterated RatingBuy ➝ Buy$36.00 ➝ $40.00High
12/10/2019Royal Bank of CanadaBoost TargetOutperform$18.00 ➝ $19.00High
12/2/2019HC WainwrightReiterated RatingBuy$44.00 ➝ $36.00Low
11/8/2019Credit Suisse GroupDowngradeOutperform ➝ Neutral$16.00 ➝ $4.00High
10/31/2019WedbushReiterated RatingBuy$38.00Medium
10/11/2019WedbushSet TargetBuy$38.00Low
9/4/2019HC WainwrightReiterated RatingBuy$44.00Low
8/11/2019Royal Bank of CanadaReiterated RatingBuyLow
7/29/2019Credit Suisse GroupLower TargetOutperform$24.00 ➝ $16.00Medium
7/18/2019WedbushReiterated RatingOutperform$38.00High
7/8/2019WedbushSet TargetBuy$38.00Low
6/19/2019WedbushReiterated RatingBuy$38.00Medium
6/5/2019HC WainwrightSet TargetBuy$44.00Medium
5/28/2019HC WainwrightReiterated RatingBuy$44.00Low
5/10/2019WedbushSet TargetBuy$38.00Medium
5/6/2019HC WainwrightReiterated RatingBuyLow
4/29/2019HC WainwrightReiterated RatingBuyLow
3/7/2019HC WainwrightSet TargetBuy$44.00Low
1/25/2019WedbushSet TargetBuy$34.00High
1/23/2019HC WainwrightSet TargetBuy$44.00Low
1/15/2019WedbushSet TargetBuy$34.00High
1/4/2019HC WainwrightSet TargetBuy$44.00Low
12/11/2018WedbushReiterated RatingBuy$34.00Low
12/10/2018HC WainwrightReiterated RatingBuy$44.00Low
10/15/2018HC WainwrightSet TargetBuy$44.00Low
10/3/2018WedbushSet TargetBuy$34.00High
9/13/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$29.00Low
8/29/2018HC WainwrightSet TargetBuy$44.00High
8/15/2018SVB LeerinkInitiated CoverageOutperform$25.00Low
8/8/2018HC WainwrightSet TargetBuy$44.00High
8/6/2018WedbushInitiated CoverageOutperform$34.00High
7/25/2018HC WainwrightSet TargetBuy$30.00Low
7/19/2018Credit Suisse GroupInitiated CoverageOutperform$24.00Low
7/16/2018HC WainwrightSet TargetBuy$30.00High
6/18/2018BMO Capital MarketsBoost TargetOutperform ➝ Outperform$23.00 ➝ $31.00High
6/12/2018BMO Capital MarketsInitiated CoverageOutperform$23.00High
6/11/2018HC WainwrightSet TargetBuy$28.00Low
5/29/2018HC WainwrightReiterated RatingBuy$28.00Medium
3/9/2018HC WainwrightReiterated RatingBuy$27.00Low
2/27/2018BMO Capital MarketsReiterated RatingBuy$24.00High
2/27/2018SVB LeerinkBoost TargetOutperform ➝ Outperform$17.00 ➝ $18.00High
2/27/2018Credit Suisse GroupReiterated RatingOutperform ➝ Buy$16.00 ➝ $18.00Low
2/5/2018HC WainwrightReiterated RatingBuy$25.00Low
1/4/2018HC WainwrightSet TargetBuy$25.00Low
12/14/2017HC WainwrightSet TargetBuy$25.00Low
(Data available from 12/7/2017 forward)

News Sentiment Rating

0.11 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
5/11/2022
  • 5 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
6/10/2022
  • 3 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
7/10/2022
  • 5 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
8/9/2022
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/8/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/8/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/7/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/7/2022

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

ObsEva logo
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.
Read More

Today's Range

Now: $0.17
Low: $0.17
High: $0.18

50 Day Range

MA: $0.18
Low: $0.14
High: $0.21

52 Week Range

Now: $0.17
Low: $0.13
High: $2.45

Volume

892,776 shs

Average Volume

1,512,448 shs

Market Capitalization

$13.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.45

Frequently Asked Questions

What sell-side analysts currently cover shares of ObsEva?

The following Wall Street sell-side analysts have issued reports on ObsEva in the last year: Aegis, Canaccord Genuity Group Inc., Cantor Fitzgerald, HC Wainwright, and StockNews.com.
View the latest analyst ratings for OBSV.

What is the current price target for ObsEva?

5 Wall Street analysts have set twelve-month price targets for ObsEva in the last year. Their average twelve-month price target is $8.40, suggesting a possible upside of 4,841.2%. Aegis has the highest price target set, predicting OBSV will reach $12.00 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of $1.00 for ObsEva in the next year.
View the latest price targets for OBSV.

What is the current consensus analyst rating for ObsEva?

ObsEva currently has 3 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in OBSV, but not buy more shares or sell existing shares.
View the latest ratings for OBSV.

What other companies compete with ObsEva?

Other companies that are similar to ObsEva include Tricida, Liminal BioSciences, Graybug Vision, Biophytis and VYNE Therapeutics. Learn More about companies similar to ObsEva.

How do I contact ObsEva's investor relations team?

ObsEva's physical mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The company's listed phone number is (122) 552-3840 and its investor relations email address is [email protected] The official website for ObsEva is www.obseva.com. Learn More about contacing ObsEva investor relations.